Targeting eosinophils in asthma: current and future state of cytokine- and chemokine-directed monoclonal therapy.
Walsh
Garry M
GM
D056151:Airway Remodeling / Q000187:drug effects; D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D001249:Asthma / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology / Q000503:physiopathology; D016535:Bronchial Hyperreactivity; D016207:Cytokines / Q000276:immunology*; D018450:Disease Progression; D004804:Eosinophils / Q000187:drug effects* / Q000276:immunology / Q000378:metabolism / Q000473:pathology; D006801:Humans; D007167:Immunotherapy / Q000639:trends; D007249:Inflammation; D058408:Th1-Th2 Balance / Q000187:drug effects
D000911:Antibodies, Monoclonal; D016207:Cytokines